ADVFN Logo
Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers
BioCardia Inc

BioCardia Inc (BCDA)

3.04
0.10
( 3.40% )
Updated: 13:00:10

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

BCDA News

Official News Only

BCDA Discussion

View Posts
JB40 JB40 2 days ago
Understand and agree. They get little to no traction on the market. Although, most important imo is they do get traction with the largest health insurer in the country putting millions into BCDA's trials. Bizarre to me that few are paying attention to such a large indication as I'm sure you are aware with them being in such a late stage of their trials. Small burn and only need a small amount of capital to get to the Phase 3 readout. They already have 90% of the Phase 3 BCDA01 data, so I guess we will see what happens with the final data set.
👍️0
murocman murocman 2 days ago
Yes. Have a personal interest as I have heart disease.

Have traded it sporadically.

Disappointed that don’t ever seem to get much traction with this therapy even with good data.

Murocman
👍️0
JB40 JB40 3 days ago
Been tracking this company for years. Anyone else?
👍️0
Monksdream Monksdream 2 weeks ago
BCDA new 52 week low
👍️0
Muhbruh Muhbruh 2 weeks ago
$BCDA catalysts;
''Our planned Morph-DNA submission to the FDA for approval of a product family from 5 French to 8 French diameters is on track for submission in the second quarter of 2024''
''Q2: Enrollment in the CardiAMP Cell Therapy Heart Failure Trial''
''Q2: Completion of low dose cohort''
''Q2: Third revenue sharing partnership agreement''
👍️0
Monksdream Monksdream 3 weeks ago
BCDA new 52 week low
👍️0
Monksdream Monksdream 3 weeks ago
BCDA new 52 week low
👍️0
tw0122 tw0122 4 weeks ago
Watching news .. 08:17 AM EDT, 06/07/2024 (MT Newswires) -- BioCardia (BCDA) said Friday that the US Patent Office has granted a patent for the company's radial and transendocardial biotherapeutic delivery catheter through 2036.

The Helix biotherapeutic delivery system is being evaluated in ongoing clinical trials, according to BioCardia. It relates to medical procedures and systems for substance delivery to the heart through a radial artery and for the intracardiac delivery of cellular aggregates and other materials, the company said.

BioCardia's stock climbed more than 44% in recent Friday premarket activity.

Price: 6.3000, Change: +1.93, Percent Change: +44.16
👍️0
Termite7 Termite7 1 month ago
Keep watching.........
👍️0
TheGreenReaper TheGreenReaper 7 months ago
Let's get a rise back up
👍️0
Triple nickle Triple nickle 8 months ago
Easy money
👍️0
Triple nickle Triple nickle 8 months ago
Grabbed 1.20
👍️0
Triple nickle Triple nickle 8 months ago
Got 1.28’s now to push it
👍️0
Triple nickle Triple nickle 8 months ago
Tapping it up
👍️0
subslover subslover 8 months ago
Already past Pluto now heading for the next solar system
👍️0
Triple nickle Triple nickle 8 months ago
1.94 in the works
👍️0
knrorrel knrorrel 8 months ago
great
👍️0
TheFinalCD TheFinalCD 8 months ago
https://dilutiontracker.com/app/search/BCDA
👍️0
TheFinalCD TheFinalCD 8 months ago
$BCDA NEWS https://finviz.com/quote.ashx?t=BCDA&p=d

https://dilutiontracker.com/app/search/BCDA
👍️0
subslover subslover 8 months ago
BioCardia Announces FDA Approval of CardiAMP Heart Failure II Protocol for Autologous Cell Therapy for Ischemic Heart Failure
SUNNYVALE, Calif., Nov. 14, 2023 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced the Food and Drug Administration (FDA) approval of its Phase III clinical trial of its CardiAMP autologous cell therapy for the treatment of patients with ischemic heart failure.

BioCardia announces that the Food and Drug Administration (FDA) has approved its proposed CardiAMP Heart Failure II study protocol. The currently ongoing CardiAMP Heart Failure trial has completed enrollment and it is anticipated that the final data analyses will be reported in Q4 2024. In an interim analysis of available data to date for study patients followed up through two years, those having N-terminal pro B-type natriuretic peptide (NT-proBNP) levels consistent as demarcating heart failure (>500 pg/ml) at screening-baseline showed meaningful clinical improvements over controls, including a 59% relative risk reduction in heart death and a 54% relative risk reduction of Major Adverse Cardiovascular or Cerebrovascular events (MACCE). Further, all clinical outcome measures evaluated at follow-up for this interim subset favored cell therapy over guideline directed medical therapy, including having improved quality-of-life as measured using the Minnesota Living with Heart Failure Questionnaire, reduced NT-proBNP levels, greater walk distance as measured using the 6-minute walk distance test, and improved cardiac measures such as left ventricular ejection fraction and left ventricular end systolic and end diastolic volumes. Statistical significance (p
👍️0
Awl416 Awl416 8 months ago
BioCardia Announces FDA Approval of CardiAMP Heart Failure II Protocol for Autologous Cell Therapy for Ischemic Heart Failure
👍️0
Biggiee Biggiee 9 months ago
Let’s do this
👍️0
Monksdream Monksdream 9 months ago
BCDA new 52 week low
👍️0
Monksdream Monksdream 10 months ago
BCDA new 52 week low
👍️0
Monksdream Monksdream 10 months ago
BCDA new 52 week low
👍️0
Monksdream Monksdream 10 months ago
BCDA new 52 week low
👍️0
Monksdream Monksdream 10 months ago
BCDA new 52 week low
👍️0
stock1ace1 stock1ace1 10 months ago
Bad news out .62 watch for the dump today
👍️0
Monksdream Monksdream 10 months ago
BCDA new 52 week low
👍️0
Monksdream Monksdream 10 months ago
BCDA new 52 week low
👍️0
Monksdream Monksdream 11 months ago
BCDA new 52 week low
👍️0
Monksdream Monksdream 11 months ago
BCDA new 52 week low
👍️0
willlbone willlbone 11 months ago
Shady day in Sunnyvale.
👍️0
PStockPickz PStockPickz 2 years ago
Nice open
👍️0
PStockPickz PStockPickz 2 years ago
Grabbed some $2.86
👍️0
PStockPickz PStockPickz 2 years ago
Time for another leg up!
👍️0
PStockPickz PStockPickz 2 years ago
https://finance.yahoo.com/news/biocardia-announces-fda-approval-ind-111500114.html
👍️0
PStockPickz PStockPickz 2 years ago
Looking good
👍️0
Awl416 Awl416 2 years ago
News
👍️0
Pro_Stock_Trader Pro_Stock_Trader 2 years ago
Going to be retesting highs here during power hour or after hours
👍️0
wesley_ wesley_ 3 years ago
$3.70 nice :)
👍️0
mplscubfan mplscubfan 3 years ago
Looking good here
👍️0
wesley_ wesley_ 3 years ago
$4.85 next leg up :)
👍️0
ClayTrader ClayTrader 4 years ago
* * $BCDA Video Chart 12-15-2020 * *

Link to Video - click here to watch the technical chart video

👍️0
ipo_dude ipo_dude 4 years ago
They anticipate .. not definitive
👍️0
Glider549 Glider549 4 years ago
Phase 3 DSMB feedback due December 17th
👍️0
ClayTrader ClayTrader 4 years ago
* * $BCDA Video Chart 12-14-2020 * *

Link to Video - click here to watch the technical chart video

👍️0
Pedro2004 Pedro2004 4 years ago
There we go. Finally broke $6.00 -- but the dump brought-it back to $5.75
👍️0
Pedro2004 Pedro2004 4 years ago
Someone keeps dumping blocks. But I'm keeping an eye on this the next few days.
👍️0
Pedro2004 Pedro2004 4 years ago
Some interesting trading this late afternoon. Low float.
👍️0

Your Recent History

Delayed Upgrade Clock